User:Adéla Fejfarová/Sandbox 1
From Proteopedia
| Line 6: | Line 6: | ||
== Physiological function of enzyme ALAS2 == | == Physiological function of enzyme ALAS2 == | ||
| - | In vertebrate organisms, there are two genes encoding ALAS enzymes that belong to α-oxoamine synthase family of pyridoxalphosphate(PLP)-dependent enzymes <ref>DOI 10.1146/annurev.biochem.73.011303.074021</ref> ALAS1 is a house-keeping gene expressed ubiquitously, in contrast ALAS2 (gene location Xp11.21) is specific for erythroid progenitor cells | + | In vertebrate organisms, there are two genes encoding ALAS enzymes that belong to α-oxoamine synthase family of pyridoxalphosphate(PLP)-dependent enzymes<ref>DOI 10.1146/annurev.biochem.73.011303.074021</ref>. ALAS1 is a house-keeping gene expressed ubiquitously, in contrast ALAS2 (gene location Xp11.21) is specific for erythroid progenitor cells<ref>10.1146/annurev.biochem.73.011303.074021</ref>. Both catalyze initial step in biosynthesis of heme cofactor. While the heme cofactor associated with proteins is essential for several physiological processes, for example transport of oxygen in red blood cells, free heme is toxic and perturbations in its metabolic pathway resulting in accumulation of intermediates lead to various blood diseases<ref>10.1101/cshperspect.a011676</ref> <ref>10.3324/haematol.2013.091991</ref>. |
=== ALAS role in heme biosynthesis === | === ALAS role in heme biosynthesis === | ||
| - | The initial and final steps of 8-step heme biosynthetic pathway take place in mitochondrial matrix. Since the ALAS mediate first reaction it is rate-limiting enzyme regulating the whole pathway, also known as a gatekeeper | + | The initial and final steps of 8-step heme biosynthetic pathway take place in the mitochondrial matrix. Since the ALAS mediate first reaction it is rate-limiting enzyme regulating the whole pathway, also known as a gatekeeper<ref>10.1016/j.bbapap.2010.12.015</ref>. It catalyzes PLP-dependent condensation of glycine and succinyl-CoA forming 5-aminolevulinic acid (ALA)<ref>10.1016/S0021-9258(19)77371-2</ref>. ALA is then transported to cytoplasm where it undergoes subsequent reactions and eventually moves back to the mitochondria to form heme<ref>10.1101/cshperspect.a011676</ref>. |
The underlying mechanism of the ALAS enzymatic reaction is induced-fit substrate binding via open-to-close conformational transition. At first, the glycine substrate binds to PLP, an active form of vitamin B6, creating an external aldimine. Following deprotonation of glycine enable nucleophilic attack on the second substrate succinyl-CoA. Consequent condensation and decarboxylation form the ALA product. The product release relies on regeneration of an internal aldimine between PLP and ALAS protein <ref>10.1074/jbc.M609330200</ref>. | The underlying mechanism of the ALAS enzymatic reaction is induced-fit substrate binding via open-to-close conformational transition. At first, the glycine substrate binds to PLP, an active form of vitamin B6, creating an external aldimine. Following deprotonation of glycine enable nucleophilic attack on the second substrate succinyl-CoA. Consequent condensation and decarboxylation form the ALA product. The product release relies on regeneration of an internal aldimine between PLP and ALAS protein <ref>10.1074/jbc.M609330200</ref>. | ||
Revision as of 15:42, 28 April 2022
ALAS2 in erythroid heme biosynthesis disorders
Enzyme 5’-aminolevulinic acid synthase (ALAS, EC 2.3.1.37) catalyzes the first step in the biosynthesis of heme molecule in alpha-proteobacteria and mitochondria of nonplant eukaryotes. In vertebrates there are two isoforms of the ALAS enzyme. The erythroid-specific ALAS2 located on chromosome X is expressed during erythropoiesis and mediates the biosynthesis of heme that carries oxygen in hemoglobin. Different mutations thorough the sequence of the enzyme lead to two ALAS2-associated blood disorders. Namely X-linked sideroblastic anemia (XLSA, MIM 300751) and X-linked protoporphyria (XLP, MIM 300752) caused typically by loss-of-function (enzyme deficiency) and gain-of-function (enzyme hyperactivity), respectively.
| |||||||||||
References
- ↑ Eliot AC, Kirsch JF. Pyridoxal phosphate enzymes: mechanistic, structural, and evolutionary considerations. Annu Rev Biochem. 2004;73:383-415. doi: 10.1146/annurev.biochem.73.011303.074021. PMID:15189147 doi:http://dx.doi.org/10.1146/annurev.biochem.73.011303.074021
- ↑ 10.1146/annurev.biochem.73.011303.074021
- ↑ 10.1101/cshperspect.a011676
- ↑ 10.3324/haematol.2013.091991
- ↑ 10.1016/j.bbapap.2010.12.015
- ↑ 10.1016/S0021-9258(19)77371-2
- ↑ 10.1101/cshperspect.a011676
- ↑ 10.1074/jbc.M609330200
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
